Concepedia

Publication | Open Access

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

DOIFull Paper Access

273

Citations

29

References

2014

Year

Michael A. Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, Zvonko Miličević
Diabetes Care

Abstract

Both dulaglutide doses demonstrated superior glycemic control versus sitagliptin at 52 weeks with an acceptable tolerability and safety profile.

References

YearCitations

Page 1